CRISPR Therapeutics AG CEO Samarth Kulkarni's 2020 pay falls 44% to $9.1M
CRISPR Therapeutics AG reports 2020 executive compensation
By ExecPay News
Published: April 28, 2021
CRISPR Therapeutics AG reported fiscal year 2020 executive compensation information on April 28, 2021.
In 2020, five executives at CRISPR Therapeutics AG received on average a compensation package of $4.4M, a 40% decrease compared to previous year.
Average pay of disclosed executives at CRISPR Therapeutics AG
Samarth Kulkarni, Chief Executive Officer, received $9.1M in total, which decreased by 44% compared to 2019. 70% of Kulkarni's compensation, or $6.3M, was in option awards. Kulkarni also received $544K in non-equity incentive plan, $625K in salary, $1.6M in stock awards, as well as $7.1K in other compensation.
Tony W. Ho, EVP, Research and Development, received a compensation package of $3.9M, which decreased by 35% compared to previous year. 61% of the compensation package, or $2.4M, was in option awards.
Lawrence O. Klein, Chief Operating Officer, earned $3.7M in 2020, a 40% decrease compared to previous year.
Michael J. Tomsicek, Chief Financial Officer, received $2.6M in 2020, which decreases by 35% compared to 2019.
James R. Kasinger, General Counsel, earned $2.6M in 2020, a 39% decrease compared to previous year.
Related executives
Samarth Kulkarni
CRISPR Therapeutics AG
Chief Executive Officer
Tony Ho
CRISPR Therapeutics AG
Former EVP, Research and Development
James Kasinger
CRISPR Therapeutics AG
General Counsel
Lawrence Klein
CRISPR Therapeutics AG
Chief Operating Officer
Michael Tomsicek
CRISPR Therapeutics AG
Chief Financial Officer
You may also like
Source: SEC filing on April 28, 2021.